Optimi Health (NASDAQ:OPTH) Upgraded at Zacks Research

Optimi Health (NASDAQ:OPTH) was upgraded by investment analysts at Zacks Research to a “hold” rating in a research note issued to investors on Thursday,Zacks.com reports.

Separately, Weiss Ratings initiated coverage on Optimi Health in a research note on Thursday, May 21st. They set a “sell (d-)” rating for the company. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Reduce”.

Optimi Health Stock Performance

NASDAQ:OPTH opened at $5.97 on Thursday. Optimi Health has a 52-week low of $4.95 and a 52-week high of $6.40.

More Optimi Health News

Here are the key news stories impacting Optimi Health this week:

• Positive Sentiment: Australia’s updated Authorized Prescriber framework broadens access to psychedelic-assisted therapy, potentially increasing demand for Optimi’s psilocybin and MDMA products in a key regulated market. Article Title
• Neutral Sentiment: Diamond Equity initiated/updated earnings estimates for multiple periods, showing expectations for continued net losses rather than an immediate path to profitability. Article Title